Close-up TV News - Prolotheray lecture

Reversing Hypertension

Heavy Metals and all diseases

Close-Up TV News - Dr. Calapai's approach

News 12 Interview: Parkinson’s Disease, Glutathione and Chelation Therapy

News 12 Interview: Platelet-rich plasma therapy

Prolotherapy Interview News 12

News 12 Interview: Diabetes and Weight Loss
Coenzyme Q10, Hyperhomocysteinemia in Patients with Parkinson’s Disease

n a study involving 60 patients with Parkinson’s disease and 82 healthy controls, increased homocysteine levels were found to “act as a mediator of the systemic oxidative stress” found in Parkinson’s disease, and the percent content of oxidized versus total coenzyme Q10 determination was found to be a possible predictor of toxic Hcy effects, which has been found to be associated with accelerated dopaminergic cell death. Furthermore, the MTHFR mutated genotype was found more frequently in patients with PD, as compared to controls. Hcy levels and % content of oxidized versus total coenzyme Q10 were found to be associated with case/control category, MTHFR genotype and their interaction term.

Published on 11-09-2012